PMID- 9738056
OWN - NLM
STAT- MEDLINE
DCOM- 19981030
LR  - 20200724
IS  - 0095-1137 (Print)
IS  - 1098-660X (Electronic)
IS  - 0095-1137 (Linking)
VI  - 36
IP  - 10
DP  - 1998 Oct
TI  - Use of molecular and reference susceptibility testing methods in a multicenter 
      evaluation of MicroScan dried overnight gram-positive MIC panels for detection of 
      vancomycin and high-level aminoglycoside resistances in enterococci.
PG  - 2996-3001
AB  - Modified MicroScan gram-positive MIC no. 8 panels (PM-8) were analyzed for their 
      improved ability to detect vancomycin resistance (VR) and high-level 
      aminoglycoside resistance (HLAR) in enterococci. A validation study design that 
      utilized selected challenge strains, recent clinical isolates, and 
      reproducibility experiments in a multicenter format was selected. Three 
      independent medical centers compared the commercial panels to reference broth 
      microdilution panels (RBM) and Synergy Quad Agar (QA). Resistance was verified by 
      demonstration of VR and HLAR genes by PCR tests. The study was conducted in three 
      phases. (i) In the challenge phase (CP), two well-characterized sets of 
      enterococci were obtained from the Centers for Disease Control and Prevention; 
      one set contained 50 isolates for VR testing and one contained 48 isolates for 
      HLAR testing. In addition, a set of 47 well-characterized isolates representing 
      diverse geographic areas, obtained from earlier national surveillance studies, 
      was tested at the University of Iowa College of Medicine (UICM). (ii) In the 
      efficacy phase (EP), each laboratory tested 50 recent, unique clinical isolates 
      by all methods. (iii) In the reproducibility Phase (RP), each laboratory tested 
      the same 10 strains by all methods in triplicate on three separate days. All 
      isolates from the EP were sent to the UICM for molecular characterization of 
      vanA, -B, -C1, -C2-3, and HLAR genes. In the CP, the ranking of test methods by 
      error rates (in parentheses; very major and major errors combined, versus PCR 
      results) were as follows: for high-level streptomycin resistance (HLSR), QA 
      (12.0%) > PM-8 (5.2%) > RBM (1.6%); for high-level gentamicin resistance (HLGR), 
      RBM (3.7%) > PM-8 (3.1%) > QA (2.6%); and for VR, RBM = QA (3.0%) > PM-8 (1.2%). 
      In the EP, agreement between all methods and the reference PCR result was 98.0% 
      for HLSR, 99.3% for HLGR, and 98. 6% for VR. In the RP, the percentages of 
      results +/- 1 log2 dilution of the all-participant mode were as follows: for VR, 
      100% (PM-8), 98.9% (QA), and 90.0% (RBM); for HLSR, 99.6% (RBM), 98.5% (PM-8), 
      and 82.2% (QA); and for HLGR, 99.6% (RBM), 99.3% (PM-8), and 98.1% (QA). The 
      ability of the PM-8 to detect VR and HLAR in enterococci was comparable to those 
      for reference susceptibility and molecular PCR methods and was considered 
      acceptable for routine clinical laboratory use.
FAU - Chen, Y S
AU  - Chen YS
AD  - Departments of Pathology, University of Iowa, Iowa City, Iowa 52242, USA.
FAU - Marshall, S A
AU  - Marshall SA
FAU - Winokur, P L
AU  - Winokur PL
FAU - Coffman, S L
AU  - Coffman SL
FAU - Wilke, W W
AU  - Wilke WW
FAU - Murray, P R
AU  - Murray PR
FAU - Spiegel, C A
AU  - Spiegel CA
FAU - Pfaller, M A
AU  - Pfaller MA
FAU - Doern, G V
AU  - Doern GV
FAU - Jones, R N
AU  - Jones RN
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Microbiol
JT  - Journal of clinical microbiology
JID - 7505564
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Gentamicins)
RN  - 6Q205EH1VU (Vancomycin)
RN  - Y45QSO73OB (Streptomycin)
SB  - IM
MH  - Anti-Bacterial Agents/*pharmacology
MH  - Drug Resistance, Microbial
MH  - Enterococcus/*drug effects/genetics/isolation & purification
MH  - Gentamicins/pharmacology
MH  - Gram-Positive Bacteria/*drug effects/genetics
MH  - Humans
MH  - Laboratories/standards
MH  - Microbial Sensitivity Tests/*methods/*standards
MH  - Quality Control
MH  - Reference Values
MH  - Reproducibility of Results
MH  - Streptomycin/pharmacology
MH  - United States
MH  - Vancomycin/*pharmacology
PMC - PMC105100
EDAT- 1998/09/17 00:00
MHDA- 1998/09/17 00:01
PMCR- 1998/10/01
CRDT- 1998/09/17 00:00
PHST- 1998/09/17 00:00 [pubmed]
PHST- 1998/09/17 00:01 [medline]
PHST- 1998/09/17 00:00 [entrez]
PHST- 1998/10/01 00:00 [pmc-release]
AID - 0479 [pii]
AID - 10.1128/JCM.36.10.2996-3001.1998 [doi]
PST - ppublish
SO  - J Clin Microbiol. 1998 Oct;36(10):2996-3001. doi: 
      10.1128/JCM.36.10.2996-3001.1998.